Back to the Blog

DermaTend Recall (2014): Mole-Removal Safety Warning

Published by

Originally published August 30, 2014. Restored and updated November 18, 2026. This article covers a historical recall and includes updated official safety information.

Solace International announced a nationwide recall of DermaTend Original and DermaTend Ultra on August 28, 2014. The products had been marketed for removing moles, warts and skin tags. This article documents that historical action.

What did the recall cover?

The recall notice preserved by Indiana’s health department covered all lots, sizes and dosage forms of DermaTend Original and Ultra. It described flexible plastic tubes with the product name printed in blue.

The recall was directed to distributors and wholesalers, while the consumer instructions called for stopping use and consulting a physician. The notice said the products were not FDA approved and had not been shown safe and effective for their labeled uses.

Why mole removal requires care

The notice warned that using these products instead of obtaining medical attention could delay diagnosis of a condition such as cancer. A mole should be evaluated by a dermatologist rather than identified and treated solely from an online description.

FDA’s current medication-health-fraud guidance also warns that unproven products marketed for removing moles and other skin lesions can cause irritation, injuries and scarring.

What to do with an old product or concern

Do not use leftover DermaTend from the recalled product line. If you have used it and have a skin injury or a concern about a growth, contact a healthcare professional. Keep the tube or a label photograph to help identify the product.

Report suspected product-related problems through FDA MedWatch. The old recall’s contact and return details have not been verified as current, so this article does not promise a refund or exchange.

Comments are subject to moderation. Please keep private contact details, account numbers, and passwords out of comments. Read our Commenting Policy.

Leave a Reply

Your email address will not be published. Required fields are marked *